|
TWI404537B
(zh)
|
2005-08-19 |
2013-08-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
ES2438496T3
(es)
|
2008-08-01 |
2014-01-17 |
Ventirx Pharmaceuticals, Inc. |
Formulaciones de agonistas de receptores de tipo toll y su uso
|
|
AU2009313392B2
(en)
|
2008-11-06 |
2016-05-05 |
Array Biopharma, Inc. |
Methods of synthesis of benzazepine derivatives
|
|
CN102781933B
(zh)
*
|
2009-08-18 |
2016-01-20 |
文蒂雷克斯药品公司 |
作为toll样受体调节剂的取代的苯并氮杂*
|
|
HUE032626T2
(en)
*
|
2009-08-18 |
2017-10-30 |
Ventirx Pharmaceuticals Inc |
Toll receptor modulator substituted benzoazepines
|
|
AU2010290896B2
(en)
|
2009-09-02 |
2014-07-03 |
Glaxosmithkline Biologicals S.A. |
Immunogenic compositions including TLR activity modulators
|
|
ES2661978T3
(es)
|
2010-05-26 |
2018-04-04 |
Selecta Biosciences, Inc. |
Vacunas multivalentes de nanovehículos sintéticos
|
|
ES2458355T3
(es)
|
2010-09-01 |
2014-05-05 |
Novartis Ag |
Adsorción de inmunopotenciadores sobre sales metálicas insolubles
|
|
EA201390660A1
(ru)
|
2010-11-05 |
2013-11-29 |
Селекта Байосайенсиз, Инк. |
Модифицированные никотиновые соединения и связанные способы
|
|
WO2012097173A2
(en)
*
|
2011-01-12 |
2012-07-19 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
BR112013022397A2
(pt)
|
2011-03-02 |
2017-09-26 |
Derek OHagan |
vacinas combinadas com doses menores de antígeno e/ou adjuvante
|
|
IN2014CN02152A
(pt-PT)
|
2011-09-01 |
2015-09-04 |
Novartis Ag |
|
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
|
|
EP2822589A1
(en)
|
2012-03-07 |
2015-01-14 |
Novartis AG |
Adjuvanted formulations of rabies virus immunogens
|
|
AU2013229432A1
(en)
|
2012-03-08 |
2014-10-16 |
Novartis Ag |
Adjuvanted formulations of booster vaccines
|
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
RU2015106930A
(ru)
|
2012-09-06 |
2016-10-20 |
Новартис Аг |
Комбинированные вакцины с менингококком серогруппы в и к/д/с
|
|
US9228184B2
(en)
|
2012-09-29 |
2016-01-05 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
US9868955B2
(en)
|
2012-09-29 |
2018-01-16 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
KR20150065878A
(ko)
|
2012-10-12 |
2015-06-15 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
조합 백신에서 사용하기 위한 가교되지 않은 무세포 백일해 항원
|
|
US9827190B2
(en)
|
2013-02-01 |
2017-11-28 |
Glaxosmithkline Biologicals Sa |
Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
|
|
JP2016521282A
(ja)
|
2013-05-10 |
2016-07-21 |
ノバルティス アーゲー |
インフルエンザワクチンにおけるナルコレプシーのリスクの回避
|
|
US10548985B2
(en)
|
2014-01-10 |
2020-02-04 |
Birdie Biopharmaceuticals, Inc. |
Compounds and compositions for treating EGFR expressing tumors
|
|
MX2016012538A
(es)
|
2014-03-26 |
2016-12-14 |
Glaxosmithkline Biologicals Sa |
Antigenos estafilococicos mutantes.
|
|
CN112546231A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
EP3166976B1
(en)
|
2014-07-09 |
2022-02-23 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
EP3097102B1
(en)
|
2015-03-04 |
2017-10-18 |
Gilead Sciences, Inc. |
Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
|
|
JP2018521016A
(ja)
|
2015-06-03 |
2018-08-02 |
アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ |
ＩＬ−２３−ｐ１９ワクチン
|
|
WO2017005851A1
(en)
|
2015-07-07 |
2017-01-12 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
|
CA2995004A1
(en)
|
2015-08-26 |
2017-03-02 |
Gilead Sciences, Inc. |
Deuterated toll-like receptor modulators
|
|
EP3349757A1
(en)
|
2015-09-15 |
2018-07-25 |
Gilead Sciences, Inc. |
Modulators of toll-like recptors for the treatment of hiv
|
|
EP3370726A4
(en)
|
2015-11-02 |
2019-06-12 |
VentiRx Pharmaceuticals, Inc. |
USE OF TLR8 AGONISTS FOR CANCER TREATMENT
|
|
AR106991A1
(es)
|
2015-12-15 |
2018-03-07 |
Gilead Sciences Inc |
Anticuerpos neutralizantes del virus de inmunodeficiencia humana
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
US11738013B2
(en)
|
2016-05-27 |
2023-08-29 |
Gilead Sciences, Inc. |
Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
EP3507276B1
(en)
|
2016-09-02 |
2021-11-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
KR102305215B1
(ko)
|
2016-10-14 |
2021-09-28 |
프리시젼 바이오사이언시스 인코포레이티드 |
B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
|
|
TWI784370B
(zh)
|
2017-01-31 |
2022-11-21 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
US11517567B2
(en)
|
2017-06-23 |
2022-12-06 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
TWI687415B
(zh)
|
2017-08-17 |
2020-03-11 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
|
CN111051305A
(zh)
|
2017-08-22 |
2020-04-21 |
吉利德科学公司 |
治疗性杂环化合物
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
EP3724222A1
(en)
|
2017-12-15 |
2020-10-21 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
JP7037667B2
(ja)
|
2017-12-20 |
2022-03-16 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
|
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CR20200347A
(es)
|
2018-02-13 |
2020-09-23 |
Gilead Sciences Inc |
Inhibidores pd-1/pd-l1
|
|
CN111836805B
(zh)
|
2018-02-15 |
2023-07-14 |
吉利德科学公司 |
吡啶衍生物及其用于治疗hiv感染的用途
|
|
KR20230145536A
(ko)
|
2018-02-16 |
2023-10-17 |
길리애드 사이언시즈, 인코포레이티드 |
레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
|
|
KR102526964B1
(ko)
|
2018-02-26 |
2023-04-28 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 복제 억제제로서의 치환된 피롤리진 화합물
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
CN112041311B
(zh)
|
2018-04-19 |
2023-10-03 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
CN118063599A
(zh)
|
2018-07-03 |
2024-05-24 |
吉利德科学公司 |
靶向hiv gp120的抗体和使用方法
|
|
EP3818052A1
(en)
|
2018-07-06 |
2021-05-12 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
CN112384283B
(zh)
|
2018-07-06 |
2023-08-15 |
吉利德科学公司 |
治疗性的杂环化合物
|
|
KR20230159715A
(ko)
|
2018-07-13 |
2023-11-21 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
CA3216031A1
(en)
|
2018-07-16 |
2020-01-23 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of hiv
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
CA3111784A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Methods and compositions for the treatment of disease with immune stimulatory conjugates
|
|
US11179397B2
(en)
|
2018-10-03 |
2021-11-23 |
Gilead Sciences, Inc. |
Imidazopyrimidine derivatives
|
|
AU2019366355B2
(en)
|
2018-10-24 |
2022-10-13 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
US11071730B2
(en)
|
2018-10-31 |
2021-07-27 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
LT3873903T
(lt)
|
2018-10-31 |
2024-05-10 |
Gilead Sciences, Inc. |
Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
|
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020178769A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
AU2020231115A1
(en)
|
2019-03-07 |
2021-08-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
CN114341185A
(zh)
|
2019-06-19 |
2022-04-12 |
希沃尔拜克治疗公司 |
抗间皮素抗体及其免疫缀合物
|
|
CR20210687A
(es)
|
2019-06-25 |
2022-03-03 |
Gilead Sciences Inc |
PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
|
|
CN114761041A
(zh)
|
2019-07-16 |
2022-07-15 |
吉利德科学公司 |
Hiv疫苗及其制备和使用方法
|
|
US20220257619A1
(en)
|
2019-07-18 |
2022-08-18 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
CN114667134A
(zh)
|
2019-08-15 |
2022-06-24 |
希沃尔拜克治疗公司 |
苯并氮杂䓬缀合物的制剂及其用途
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
KR20220074917A
(ko)
|
2019-09-30 |
2022-06-03 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 백신 및 hbv를 치료하는 방법
|
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
TW202124450A
(zh)
|
2019-10-18 |
2021-07-01 |
美商四十七股份有限公司 |
用於治療骨髓發育不良症候群及急性骨髓白血病之組合療法
|
|
JP2023500639A
(ja)
*
|
2019-10-31 |
2023-01-10 |
エフ．ホフマン－ラ ロシュ アーゲー |
自己免疫疾患の処置用のヒドロピラジノ［１，２－ｄ］［１，４］ジアゼピン化合物
|
|
JP2022552748A
(ja)
|
2019-10-31 |
2022-12-19 |
フォーティ セブン， インコーポレイテッド |
抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
KR20220106165A
(ko)
|
2019-11-26 |
2022-07-28 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 예방을 위한 캡시드 억제제
|
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
WO2021130638A1
(en)
|
2019-12-24 |
2021-07-01 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2021163064A2
(en)
|
2020-02-14 |
2021-08-19 |
Jounce Therapeutics, Inc. |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
|
EP4106819A1
(en)
|
2020-02-21 |
2022-12-28 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
JP2023518433A
(ja)
|
2020-03-20 |
2023-05-01 |
ギリアード サイエンシーズ， インコーポレイテッド |
４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
|
|
KR20230006891A
(ko)
|
2020-05-01 |
2023-01-11 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73를 억제하는 2,4-다이옥소피리미딘 화합물
|
|
WO2021236944A1
(en)
|
2020-05-21 |
2021-11-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
CA3181690A1
(en)
|
2020-06-25 |
2021-12-30 |
Chienhung CHOU |
Capsid inhibitors for the treatment of hiv
|
|
CA3183993A1
(en)
|
2020-07-01 |
2022-01-06 |
Peter R. Baum |
Anti-asgr1 antibody conjugates and uses thereof
|
|
AU2021320236A1
(en)
|
2020-08-07 |
2023-04-13 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
EP4244396A1
(en)
|
2020-11-11 |
2023-09-20 |
Gilead Sciences, Inc. |
Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CN117203238A
(zh)
|
2021-04-23 |
2023-12-08 |
普方生物制药美国公司 |
Cd70结合剂、其偶联物及其使用方法
|
|
EP4337223A1
(en)
|
2021-05-13 |
2024-03-20 |
Gilead Sciences, Inc. |
Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
|
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
|
EP4359389A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222439A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
CA3234909A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
WO2023077030A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
TW202342447A
(zh)
|
2021-12-03 |
2023-11-01 |
美商基利科學股份有限公司 |
用於ｈｉｖ病毒感染之治療性化合物
|
|
WO2023102529A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
|
TW202337439A
(zh)
|
2021-12-03 |
2023-10-01 |
美商基利科學股份有限公司 |
用於ｈｉｖ病毒感染之治療性化合物
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
US20230242508A1
(en)
|
2021-12-22 |
2023-08-03 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
US20230373950A1
(en)
|
2022-03-17 |
2023-11-23 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023183817A1
(en)
|
2022-03-24 |
2023-09-28 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
TW202400172A
(zh)
|
2022-04-06 |
2024-01-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US20240034724A1
(en)
|
2022-07-01 |
2024-02-01 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
WO2024044477A1
(en)
|
2022-08-26 |
2024-02-29 |
Gilead Sciences, Inc. |
Dosing and scheduling regimen for broadly neutralizing antibodies
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024076915A1
(en)
|
2022-10-04 |
2024-04-11 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
|
WO2024137852A1
(en)
|
2022-12-22 |
2024-06-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|